Haleon Regulatory News (HLN)

Haleon plc: Proposed off-market purchase alongside Pfizer Inc. offering

30 September 2024: Haleon plc (the "Company" or "Haleon") (LSE/NYSE: HLN) notes the announcement today by Pfizer Inc. ("Pfizer") of its proposed offering of ordinary shares of £0.01 each in the Company to institutional investors by way of an accelerated bookbuild offering process (the "Proposed Offering").

Haleon has agreed with Pfizer to make an off-market purchase of approximately £230 million worth of ordinary shares from Pfizer, subject to completion of the Proposed Offering. The purchase price per ordinary share to be paid by Haleon in the off-market purchase will be equal to the offering price per ordinary share in the Proposed Offering.

The off-market purchase includes approximately £114.6 million worth of ordinary shares, which represents the remainder of the £500 million allocated to share buybacks in 2024 announced on 29 February 2024. Haleon intends to cancel these ordinary shares and end its on-market share buyback programme launched on 1 August 2024.

Separate to the remaining capital allocated to buybacks in 2024, the off-market purchase includes approximately £115.4 million worth of ordinary shares that will be held as treasury shares for the purposes of satisfying Haleon's obligations under its existing employee share plans in 2025.

Further details will be provided following announcement by Pfizer of the results of the Proposed Offering.

Amanda Mellor 

Company Secretary 

Enquiries

About Haleon

Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans five major categories - Oral Health, Pain Relief, Respiratory Health, Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax and Centrum - are built on trusted science, innovation and deep human understanding.

For more information please visit www.haleon.com

Not for release, publication or distribution in the United States, Canada, Japan, Australia or any other state or jurisdiction in which such release, publication or distribution would be unlawful.